Form 4: Catalyst Pharma CCO Del Carmen's RSU Vesting

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, reported the vesting of 8,039 restricted stock units and subsequent share transactions.

Summary

• Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported changes in beneficial ownership.
• On December 8, 2025, 8,039 restricted stock units (RSUs) vested, leading to the acquisition of 8,039 shares of common stock.
• Concurrently, 2,492 shares of common stock were disposed of to satisfy applicable withholding taxes.
• Following these transactions, Del Carmen beneficially owns 9,509 shares of common stock directly.
• He also beneficially owns 1,045,513 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine compensation, indicating continued executive alignment, but doesn't provide new operational or financial insights. The slight positive comes from an executive receiving shares, which is generally seen as a good sign of commitment.

Positives

• Chief Commercial Officer Jeffrey Del Carmen received 8,039 shares of common stock through the vesting of restricted stock units, aligning his interests with shareholders.

Negatives

• 2,492 shares were withheld by the company to cover applicable withholding taxes, reducing the net shares received by the officer.

Future Outlook

Remaining Restricted Stock Units are scheduled to vest in equal tranches, with the final tranche vesting on December 8, 2026. Shares of common stock are required to be delivered within sixty days of vesting.

Industry Context

This filing reports a routine insider transaction related to executive compensation, which is a standard practice across the pharmaceutical industry to align executive incentives with shareholder value. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: Minor positive impact due to continued alignment of executive incentives with company performance through equity compensation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The remaining 1/3rd tranche of Restricted Stock Units is scheduled to vest on December 8, 2026.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Jeffrey Del Carmen, Form 4, SEC Filing, Restricted Stock Units, RSU Vesting, Insider Transaction, Beneficial Ownership, Chief Commercial Officer